Table 4.
Capability of the three snoRNA genes to discriminate NSCLC patients from healthy controls and COPD patients*
| Distinguishing NSCLC from healthy subjects | Distinguishing NSCLC from COPD | |||||||
|---|---|---|---|---|---|---|---|---|
| SnoRNAs | AUC (SE) | Thresholds | Sensitivity | Specificity | AUC (SE) | Thresholds | Sensitivity | Specificity |
| % | % | % | % | |||||
| SNORD33 | 0.8233 (0.06) | 0.23 | 72.97 | 86.36 | 0.82 (0.05) | 0.23 | 72.97 | 84.62 |
| SNORD66 | 0.8139 (0.046) | 0.99 | 75.68 | 77.27 | 0.7903 (0.04) | 1.00 | 72.97 | 80.77 |
| SNORD76 | 0.8064 (0.03) | 133.65 | 70.27 | 90.91 | 0.8149 (0.06) | 136.14 | 70.27 | 88.46 |
| The three genes used in combination | 0.89 (0.06) | 83.78 | 95.45 | 0.88 (0.06) | 81.08% | 96.15% | ||
* Receiver-operator characteristic (ROC) curve and the area under ROC curve (AUC) analyses were applied to determine optimal thresholds that define expression levels of the tested genes, yielding corresponding maximum sensitivity and specificity of each gene in diagnosis of NSCLC from either healthy or COPD individuals.
Abbreviations: NSCLC, non-small-cell lung cancer; COPD, chronic obstructive pulmonary disease; SD, standard deviation; SE, standard error.